Loading
A phase 1/2 trial of CP-383 in colorectal cancer, small-cell lung cancer, head and neck squamous cell carcinoma, bladder & urothelial cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Tasca Therapeutics, now recruiting.
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07030257 by Tasca Therapeutics, with 150 participants planned, started 2025-08-27 and due to reach its primary completion in 2028-08-15. Interventions recorded: CP-383.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/